Cuba conducts clinical trial of Jusvinza for treating Chikungunya
- Written by Redacción ¡ahora!
- Published in Health
- Hits: 25
Cuban health authorities have begun a clinical trial of the drug Jusvinza, developed by the Center for Genetic Engineering and Biotechnology, to treat residual polyarthritis in patients recovering from Chikungunya, the Biocubafarma Group announced on its Facebook profile.
The Ministry of Public Health reported that the research was approved by the Health Innovation Committee and is being conducted in four hospitals in the provinces of Havana and Matanzas.
The main objective is to evaluate the efficacy of the synthetic immunoregulatory peptide in reducing joint pain and inflammation, one of the most frequent and prolonged aftereffects of the disease.
Jusvinza was initially conceived as a treatment for rheumatoid arthritis and, during the COVID-19 pandemic, was used in Cuba to control hyperinflammation in severely and critically ill patients, according to official data.
The current trial is the first of its kind in the country focused on the sequelae of Chikungunya and is part of a broader national plan for the control of arboviruses, which includes epidemiological surveillance, updated clinical protocols, and control of the transmitting mosquito.
Specialists indicated that the research aims to provide scientific evidence on the drug's usefulness in a health context where vector-borne diseases represent a public health challenge.
